Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)

NCT03070093 · clinicaltrials.gov ↗

APPROVED_FOR_MARKETING

Status

INDUSTRY

Sponsor class

Conditions

Acute Myeloid Leukemia (AML)
FMS-like Tyrosine Kinase-3 (FLT3) Mutations

Interventions

DRUG: gilteritinib

Sponsor

Astellas Pharma Global Development, Inc.